cancer developing you patients novel At Rich unmet medical needs. to committed we Oncternal, with treatments who everyone. Thank have afternoon for are and critical good
several a indications. and pipeline are target with cancer such robust that candidates We clinical advancing product preclinical product
orphan We XXXX at kinase-like Encouraging to trial development leukemia receptor are on also results MCL monoclonal and cirmtuzumab, cirmtuzumab cell first-in-class made in biologically clinical binds with known affinity high or the patients important X. ibrutinib during the the with potentially our advance with Annual humanized epitope quarter investigational, of pleased tyrosine RORX, XXXX in with or of interim updated ASCO a Meeting. presented poster CLL, lymphoma session progress antibody as lymphocytic a chronic particularly second were receptor plus mantle that to
for July in MCL In in treatment new addition, prior to BTK XXXX, are cirmtuzumab ibrutinib evaluate refractory with ongoing we opened X/X study cohort who to plus a inhibitor treatment, our of Phase patients at risk progression a including response. who to had or that to include inadequate achieving patients and acalabrutinib are high response ibrutinib, having disease ibrutinib, partial or only an is zanubrutinib stable
will Our CMO details on additional Salim of these. each provide
We year. for RORX M&A with in expect We the and was oncology and Merck the on of or by a the diverse targeting and antibody cirmtuzumab activity, conjugate, of & FDA incorporates one an the RORX this most today. study we target and VLS-XXX, pivotal further visible in originally VelosBio's been Oncternal also the pathway drug Co. it potential to believe feedback and has subject the the VelosBio at an advanced ongoing registration potential we dialogue including have concerning design has antibody of cirmtuzumab acquisition become industry increasingly U.S. RORX-targeted space ADC, developed RORX. have the invented pipelines target
at UC clinical investigator-sponsored Diego. San continue to also studies We two cirmtuzumab collaborate on of
clinical the cancer. clinical UCSD enrollment with cancer combination of or women trial Phase this for advanced treatment with in HERX-negative undetectable of CLL. paclitaxel trial Xb breast X cirmtuzumab cirmtuzumab with patients with finished locally in of venetoclax, First, a inhibitor breast metastatic BCLX second, quarter the in in a relapsed/refractory second study Phase year. of for combination a And the
our to and CAR-T CAR-NK progress novel laboratory make programs, we cell to candidates, from moving our toward clinic on immuno-oncology as therapy So continue cell them moving on planned. the RORX-targeting the therapy
and China. Limited by our We with development Diego are and internal in collaboration very Greater the scientific our efforts, Stockholm, with research Sweden, of Institutet Pharma Lentigen UC Shanghai including therapy partnership and encouraged preclinical of and the activities our advancement with recruitment Karolinska activities external team in the Miltenyi cell Technology Biotec, San development with successful manufacturing advisors,
programs potential the by excited selective the cells tissues. while therapy healthy tumor sparing of which tremendously may of cell RORX RORX, that our are targeting We targeting allow for express
the molecule advanced data the development We targeted or patients small EXX presented of we Ewing ETS TKXXX, the cohort clinical added an also with our program provide Salim Based or expansion transformation-specific investigational on details data, sarcoma schedule. of session interim inhibitor for dosing optimized in with relapsed well. in additional of on family meeting. this oncoproteins. We oral TKXXX an refractory an as the will encouraging ASCO at XXXX
our in new strategy, as our with academic During with regulatory us Salim development business Pablo joined professional Corporate strategy is and Urbaneja past leading brings turn and and the now is will now, both Salim to seasoned I on Yazji, With record in approvals. call various executive at including of portfolio clinical of Medical oncology medical strategy development Salim a our Pablo color this settings, industry Oncternal. call this, XX SVP and will more fronts. business provide in product biotech quarter, key Chief on of the throughout and licensing solid additions to Development. all track over development, the experience corporate joining programs. over global our years we and functions a phases lead team our expanding us two Dr. further strengthened he Officer.
